vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and OCTAVE SPECIALTY GROUP INC (OSG). Click either name above to swap in a different company.
BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $104.2M, roughly 1.5× OCTAVE SPECIALTY GROUP INC). On growth, OCTAVE SPECIALTY GROUP INC posted the faster year-over-year revenue change (66.0% vs 7.5%). Over the past eight quarters, OCTAVE SPECIALTY GROUP INC's revenue compounded faster (42.9% CAGR vs 19.6%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Octave Specialty Group Inc. is a specialty insurance holding company that provides tailored property and casualty insurance products. Its core business focuses on excess and surplus lines, catering to commercial and individual clients across primary North American markets with customized risk coverage solutions.
BCRX vs OSG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $104.2M |
| Net Profit | — | $-6.9M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | — |
| Net Margin | — | -6.6% |
| Revenue YoY | 7.5% | 66.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $104.2M | ||
| Q4 25 | $406.6M | $66.9M | ||
| Q3 25 | $159.4M | $66.6M | ||
| Q2 25 | $163.4M | $55.0M | ||
| Q1 25 | $145.5M | $62.8M | ||
| Q4 24 | $131.5M | $65.2M | ||
| Q3 24 | $117.1M | $70.0M | ||
| Q2 24 | $109.3M | $51.0M |
| Q1 26 | — | $-6.9M | ||
| Q4 25 | $245.8M | $-29.7M | ||
| Q3 25 | $12.9M | $-112.6M | ||
| Q2 25 | $5.1M | $-72.7M | ||
| Q1 25 | $32.0K | $-44.7M | ||
| Q4 24 | $-26.8M | $-20.9M | ||
| Q3 24 | $-14.0M | $-27.5M | ||
| Q2 24 | $-12.7M | $-750.0K |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | -76.7% | ||
| Q3 25 | 18.6% | -48.2% | ||
| Q2 25 | 18.2% | -41.8% | ||
| Q1 25 | 14.6% | -24.1% | ||
| Q4 24 | -3.4% | -55.5% | ||
| Q3 24 | 6.6% | -29.7% | ||
| Q2 24 | 8.0% | -28.9% |
| Q1 26 | — | -6.6% | ||
| Q4 25 | 60.5% | -73.8% | ||
| Q3 25 | 8.1% | -169.1% | ||
| Q2 25 | 3.1% | -132.3% | ||
| Q1 25 | 0.0% | -71.3% | ||
| Q4 24 | -20.4% | -55.1% | ||
| Q3 24 | -12.0% | -39.3% | ||
| Q2 24 | -11.6% | -1.5% |
| Q1 26 | $0.00 | $-0.13 | ||
| Q4 25 | $1.13 | $-0.82 | ||
| Q3 25 | $0.06 | $-2.35 | ||
| Q2 25 | $0.02 | $-1.54 | ||
| Q1 25 | $0.00 | $-1.22 | ||
| Q4 24 | $-0.13 | $-11.75 | ||
| Q3 24 | $-0.07 | $-0.63 | ||
| Q2 24 | $-0.06 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | — |
| Total DebtLower is stronger | — | $117.1M |
| Stockholders' EquityBook value | — | $833.6M |
| Total Assets | $465.1M | $2.3B |
| Debt / EquityLower = less leverage | — | 0.14× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $146.4M | ||
| Q3 25 | $212.9M | $27.5M | ||
| Q2 25 | $260.0M | $22.5M | ||
| Q1 25 | $295.1M | $34.1M | ||
| Q4 24 | $320.9M | $157.2M | ||
| Q3 24 | $96.8M | $40.8M | ||
| Q2 24 | $78.4M | $14.6M |
| Q1 26 | — | $117.1M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $518.0M | ||
| Q2 24 | — | $515.0M |
| Q1 26 | — | $833.6M | ||
| Q4 25 | $-119.2M | $715.8M | ||
| Q3 25 | $-387.9M | $843.4M | ||
| Q2 25 | $-421.6M | $859.8M | ||
| Q1 25 | $-451.9M | $852.2M | ||
| Q4 24 | $-475.9M | $798.4M | ||
| Q3 24 | $-468.6M | $1.5B | ||
| Q2 24 | $-475.6M | $1.4B |
| Q1 26 | $465.1M | $2.3B | ||
| Q4 25 | $514.2M | $2.2B | ||
| Q3 25 | $446.4M | $2.1B | ||
| Q2 25 | $457.2M | $8.5B | ||
| Q1 25 | $480.0M | $8.3B | ||
| Q4 24 | $490.4M | $8.1B | ||
| Q3 24 | $491.3M | $9.3B | ||
| Q2 24 | $472.4M | $8.2B |
| Q1 26 | — | 0.14× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
